Intimation of Press release regarding unaudited financial results of H1FY27.

November 05, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot No. C/1, Dalal Street, Fort, G Block, Bandra - Kurla Complex, Mumbai – 400 001 Bandra (East), Mumbai 400 051 Scrip Code: 506414 Trading Symbol: FERMENTA Dear Sir, Sub: Press Release Please find enclosed herewith a ‘Press Release’ issued by the Company regarding unaudited financial results of H1FY27. Kindly take the above on record. Thanking you, Yours faithfully, For Fermenta Biotech Limited Varadvinayak Khambete Company Secretary & Head - Legal Membership No. A33861 Encl: As above Press Release Fermenta H1FY27 Consolidated Revenue INR 261.9 crore; down 7% YoY BSE: 506414 NSE: FERMENTA Bloomberg: FERMENTA:IN Reuters: FERM.BO  Human Nutrition has grown in overall revenue share: and is now close to two- thirds of overall revenue  With low animal nutrition prices, sales volumes of animal nutrition products have not been pursued  Consolidated Revenue down 7% YoY and EBITDA down 34% YoY, primarily due to lower animal nutrition business and prior year EBITDA benefiting from in- surance income, real estate value unlocking and foreign exchange gains  “As India business contribution has risen to 51% of consolidated revenue in H1FY27 from 40% a year earlier, Fermenta is consciously building on its stead- ier markets while animal nutrition works through its price cycle.”: Prashant Nagre, Managing Director Mumbai, 05 November 2026: Fermenta Biotech Limited, one of the world’s largest manufacturers of Vitamin D3 API, and a growing portfolio of premium-grade nutri- tional ingredients, green chemistry, APIs and intermediates, today announced its re- sults for the quarter & half year ended 30 September 2026. On the consolidated basis H1FY27 revenue was INR 261.9 crore (down 7% YoY), EBITDA INR 45.6 crore (down 34% YoY), and Profit after Tax INR 18.9 crore (down 52% YoY). Most of the year-on-year fall in Revenue & EBITDA traces to animal nutri- tion pricing and to one-off income in the base period. Unless stated otherwise, all figures in this release are for the period April–September 2026 (H1FY27); year-on-year comparisons are against April–September 2025 (H1FY26). Consolidated Key financials Q2FY27 H1FY27 Revenue INR 135.8 crore INR 261.9 crore (up 0.1% YoY, up 8% QoQ) (down 7% YoY) EBITDA INR 23.2 crore INR 45.6 crore (down 28% YoY, up 3% QoQ) (down 34% YoY) Profit after tax INR 9.4 crore INR 18.9 crore (down 48% YoY, down 1% QoQ) (down 52% YoY) EPS (diluted) Rs. 3.34 Rs. 6.67 Consolidated Revenue mix H1FY27 H1FY26 YoY change (%) (INR crore) (INR crore) Nutrition Business Vitamin D3 – Human Nutrition 162.5 158.8 +2% Vitamin D3 – Animal Nutrition 22.1 46.2 -52% Others 24.0 15.2 +58% Other Business Other APIs and Intermediates 22.5 22.9 -1% Green Chemistry Solutions / 3.2 3.5 -8% Enzymes Environmental Solutions 16.6 15.1 +10% Other Income 11.0 17.5 -37% Value Unlocking Real Estate 0 1.6 -100% Geographical Revenue Mix (consolidated) excluding real estate value un- locking H1FY27 H1FY26 Change (%) India 51% 40% +11% Europe 21% 29% -8% North America 9% 13% -3% Others 18% 18% 0% Performance highlights for H1FY27  Human nutrition segment grew by 2% despite the reduction in volumes by 13% YoY.  Animal nutrition segment volumes were down 31% YoY, with average realisation down 35% YoY.  Other Income was INR 7.5 crore against INR 14.2 crore a year earlier. The base period included a non-recurring insurance claim of INR 2.7 crore together with higher foreign exchange gains. Other Income sits above EBITDA and is therefore already reflected in the EBITDA movement reported above.  Our German subsidiary's H1FY27 revenue was INR 13.1 crore, down 62% YoY, with EBITDA at INR 2.5 crore loss, down from INR 7.8 crore profit YoY. Our US trading busi- ness subsidiary's H1FY27 revenue was INR 17.2 crore, down 43% YoY, with EBITDA at INR 1.0 crore loss, down by INR 0.9 crore YoY. Our Environment subsidiary's H1FY27 revenue was INR 16.7 crore, with EBITDA at INR 4.7 crore loss, down by INR 2.0 crore YoY.  VITADEE Green®, Fermenta’s plant-source Vitamin D3, received FSSAI approval on 6 July 2026 for use as an ingredient in health supplements, nutraceuticals, food prod- ucts and large scale food fortification, opening India’s large vegetarian consumer base to a domestically manufactured, patent-backed Vitamin D3.  On 4 August 2026, Fermenta Biotech Limited listed on National stock exchange (NSE) Commenting on the results, Prashant Nagre, Managing Director, said: “The first half tested the balance of our business. Vitamin D3 prices in animal nutrition fell by about a third, and the comparison year carried income that did not repeat. Through that, Hu- man Nutrition, now close to two-thirds of our revenue, grew 2%, and its volumes rose 7% se- quentially over Q1FY27, strengthening Fermenta’s focus on Human Nutrition. India is now our largest market, at 51% of revenue. The FSSAI approval for VITADEE Green® opens the country’s large vegetarian consumer base to a domestically manufactured, patent- backed Vitamin D3, the capacities for which should be available from Q2FY28. Vitamin D3 an- alog product Calcifediol is expected to be ready for regulatory approvals by the end of FY27. Our listing on the NSE has broadened access to Fermenta for investors.” About Fermenta Biotech Limited (www.fermentabiotech.com) is one of the world’s largest manu- facturers of Vitamin D3 API, with a growing portfolio of premium-grade nutritional ingredi- ents, green chemistry solutions, APIs and intermediates. Manufacturing facilities at Kullu (Himachal Pradesh), Dahej (Gujarat) and Tirupati (Andhra Pradesh), supported by the R&D Excellence Centre at Thane, serve over 400 customers in more than 60 countries meeting IP, USP, Ph. Eur. and FCC standards. Environmental solutions are delivered through the wholly owned subsidiary Fermenta Environment Solutions Private Limited. The Company’s two flag- ship introductions, VITADEE Green® plant-source Vitamin D3 and the Vitamin D3 100 SD pre- mix, are supported by a granted Indian process patent, an EDQM Certificate of Suitability, and commercial-scale capacity being established at Dahej. Disclaimer No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this release. Such information and opinions are in all events not current after the date of this release. Certain statements made in this release may not be based on historical infor- mation or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the manage- ment of Fermenta Biotech Limited (“Company” or “FBL” or Fermenta), which are expressed in good faith and in their opinion reasonable, including those relating to the Company’s general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial con- dition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company’s business, its competitive environment and political, economic, legal and social conditions. Fur- ther, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this release are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obli- gation to update these forward-looking statements to reflect future events or developments. This release is for general infor- mation purposes only, wi [Showing first 8,000 characters — download PDF for full document]